ReviewBritish journal of clinical pharmacology2018
New-onset epilepsy in the elderly.
Review in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- A European Academy of Neurology guideline on medical management issues in dementia.European journal of neurology · 2020Guideline
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
- Seizures as the initial presentation of cerebral venous sinus thrombosis in an elderly patient: a case report and literature review.Annals of medicine and surgery (2012) · 2026Article
- Tau pathology in epilepsy: emerging mechanisms and translational opportunities.Brain : a journal of neurology · 2026Review
- Frailty and outcomes in older adults hospitalized for epilepsy: a nationwide inpatient sample study.BMC geriatrics · 2026Article
- The Impact of Social Support on Anxiety and Depression in Persons with Epilepsy (PWE).Advances in experimental medicine and biology · 2026Article
- Epilepsy and EEG abnormalities in neurodegenerative dementias: toward a system epilepsy framework.Frontiers in aging neuroscience · 2026Review
- Depression in older adults with epilepsy: Pathophysiology and management considerations.Epilepsy & behavior : E&B · 2025Review
- Epilepsy and systemic autoimmune diseases: A bidirectional two-sample Mendelian randomization study.Epilepsia open · 2025Article
- Comparison of Glutathione, Retinol and α- and γ-Tocopherols Concentrations Between Children with and Without Epilepsy: A Single-Center Case-Control Study.Brain sciences · 2025Article
- Clinical Features and Prognostic Analysis of Elderly Patients With Late-Onset Epilepsy.Brain and behavior · 2025Article
- Analysis of the Correlation between Frailty Index, Clinical Characteristics, Use of Anti-Epileptic Drug, and Prognosis in Elderly Patients with Epilepsy.Actas espanolas de psiquiatria · 2025Article
- Prognosis of people with focal epilepsy treated with anti-seizure medications (ASMs): a narrative review of current evidence and future directions.BMJ neurology open · 2025Review
- Association of Seizure Control With Cognition in People With Normal Cognition and Mild Cognitive Impairment.Neurology · 2024Article
- Challenges and prospects in geriatric epilepsy treatment: the role of the blood-brain barrier in pharmacotherapy and drug delivery.Frontiers in aging neuroscience · 2024Review
- Association of first anti-seizure medication choice with injuries in older adults with newly diagnosed epilepsy.Seizure · 2023Article
- Selected Biomarkers of Oxidative Stress and Energy Metabolism Disorders in Neurological Diseases.Molecular neurobiology · 2023Review
- Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy.Frontiers in neurology · 2023Article
- Hyperperfusion Tmax mapping for nonconvulsive status epilepticus in the acute setting: A pilot case-control study.Epilepsia · 2022Article
- Decreased synapse-associated proteins are associated with the onset of epileptic memory impairment in endothelialMedComm · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
People who are 60 years old and older have the highest incidence of developing new-onset epilepsy. The increase of the ageing population has resulted in a greater number of patients with new-onset epilepsy or at risk of developing the condition. Previously published review articles regarding epilepsy in older patients have had a broad focus, including people who were diagnosed with epilepsy in their childhood or middle age. The present review focuses on the causes, treatment, prognosis and psychosocial impact of new-onset epilepsy in people aged ≥60 years. Following a search of the medical electronic databases and relevant references, we identified 22 studies overall that met the inclusion criteria. Only four randomized clinical trials (RCTs) were identified that compared different antiepileptic drug treatments in this population, demonstrating that newer-generation antiepileptic drugs (e.g. lamotrigine and levetiracetam) were generally better tolerated. One uncontrolled study provided promising evidence of good outcomes and safety for surgical resection as a treatment for people with uncontrolled seizures. Five studies reported that people ≥60 years with new-onset epilepsy have significant cognitive impairments (e.g. memory loss) and psychological issues including depression, anxiety and fatigue. We found that there is limited evidence to guide treatment in people with Alzheimer's disease and epilepsy. The specific features of new-onset epilepsy in this target population significantly influences the choice of treatment. Cognitive and psychiatric screening before treatment may be useful for management. Two studies with proposed guidelines were identified but no formal clinical practice guidelines exist for this special population to assist with appropriate management. There is a need for more RCTs that investigate effective treatments with limited side effects. More research studies on the psychosocial effects of new-onset epilepsy, and long-term outcomes, for people aged ≥60 years are also required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.